Interní Med. 2016; 18(1): 9-13 | DOI: 10.36290/int.2016.003

Detection of early stages of atherosclerosis

doc. MUDr. Jan Piťha, CSc.
Laboratoř pro výzkum aterosklerózy, Centrum experimentální medicíny, Institut klinické a experimentální medicíny, Praha

One of the main efforts of preventive cardiology is to detect persons at high cardiovascular risk yet before clinical manifestation of atherosclerosis, which could be fatal. In general, three approaches are discussed: 1) Algorithms calculating the risk of cardiovascular events based on traditional cadiovascular risk factors, 2) Measurements of the concentration of circulating biomarkers, including genetic parameters and 3) Morphological and functional methods assessing vascular wall or obstructive lesions; this group often labelled as detection of preclinical atherosclerosis. The contribution of these approaches could be viewed from several aspects. The most important aspect is whether particular method could help in decision to implement aggressive pharmacologic therapy focused mainly on higher levels of LDL cholesterol or high blood pressure. Historically accepted approaches are established algorithms based on traditional risk factors. More recent methods contribute to the better assessment of cardiovascular risk only moderately. In more complicated patients, however, these approaches/methods could help with treatment decisions. From this perspective the most reliable are measurement of ankle brachial index, detection of preclinical atherosclerosis at the carotid arteries by ultrasound, the pulse wave velocity and calcium score of coronary arteries.

Keywords: cardiovascular events, early atherosclerosis, vascular biomarkers, methods of detection

Published: February 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Piťha J. Detection of early stages of atherosclerosis. Interní Med. 2016;18(1):9-13. doi: 10.36290/int.2016.003.
Download citation

References

  1. Kannel WB, Schatzkin A. Sudden death: lessons from subsets in population studies. J Am Coll Cardiol. 1985; 5(6 Suppl): 141B-149B. Go to original source... Go to PubMed...
  2. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowledge. J Am Coll Cardiol. 2009; 54(17): 1561-1575. Go to original source... Go to PubMed...
  3. Ferenczi EA, Asaria P, Hughes AD, et al. Can a Statin Neutralize the Cardiovascular Risk of Unhealthy Dietary Choices? Am J Cardiol. 2010; 106(4): 587-592. Go to original source... Go to PubMed...
  4. Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis. 2015; 241(2): 507-532. Go to original source... Go to PubMed...
  5. Conroy RM, Pyorala K Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 987e1003. Go to original source... Go to PubMed...
  6. Cook NR, Paynter NP, Eaton CB, et al. Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative. Circulation. 2012; 125(14): 1748-1756. Go to original source... Go to PubMed...
  7. Siontis GC, Tzoulaki I, Siontis KC, et al. Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ. 2012; 344: e3318. Go to original source... Go to PubMed...
  8. Hoefer IE, Steffens S, Ala-Korpela M, et al. ESC Working Group Atherosclerosis and Vascular Biology. Novel methodologies for biomarker discovery in atherosclerosis. Eur Heart J. 2015; 36(39): 2635-2642. Go to original source... Go to PubMed...
  9. Abdelhafiz AH, Ahmed S, El Nahas M. Microalbuminuria: marker or maker of cardiovascular disease. Nephron Exp Nephrol. 2011; 119(Suppl 1): e6-10. Go to original source... Go to PubMed...
  10. Hermans MP. Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD. Diab Vasc Dis Res.2011; 8(3): 180-189. Go to original source... Go to PubMed...
  11. Smith JA, Ware EB, Middha P, et al. Current Applications of Genetic Risk Scores to Cardiovascular Outcomes and Subclinical Phenotypes. Curr Epidemiol Rep. 2015; 2(3): 180-190. Go to original source... Go to PubMed...
  12. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014; 23(R1): R89-98. Go to original source... Go to PubMed...
  13. Griffin M, Nicolaides AN, Belcaro G, et al. Cardiovascular risk assessment using ultrasound: the value of arterial wall changes including the presence, severity and character of plaques. Pathophysiol Haemost Thromb. 2002; 32(5-6): 367-370. Go to original source... Go to PubMed...
  14. Auzký O, Dembovská R, Mrázková J, et al. Relation between preclinical atherosclerosis and venous thromboembolism in patients with thrombophilias - longitudinal study. Physiol Res. 2014; 63(Suppl 3): S403-409. Go to original source...
  15. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts), Eur. Heart J. 2012; 33: 1635e1701.
  16. Homma S, Hirose N, Ishida H, et al. Carotid plaque and intima media thickness assessed by b-mode ultrasonography in subjects ranging from young adults to centenarians. Stroke. 2001; 32: 830e835. Go to original source... Go to PubMed...
  17. Nasir K, Bittencourt MS, Blaha MJ, et al. Implications of Coronary Artery Calcium Testing Among Statin Candidates According to American College of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2015; 66(15): 1657-1668. Go to original source... Go to PubMed...
  18. Hutcheson JD, Maldonado N, Aikawa E. Small entities with large impact:microcalcifications and atherosclerotic plaque vulnerability. Curr Opin Lipidol. 2014; 25(5): 327-332. Go to original source... Go to PubMed...
  19. Ripa RS, Kjaer A. Imaging atherosclerosis with hybrid positron emission tomography/magnetic resonance imaging. Biomed Res Int. 2015; 2015: 914516. Go to original source... Go to PubMed...
  20. Alie N, Eldib M, Fayad ZA, et al. Inflammation, Atherosclerosis, and Coronary Artery Disease: PET/CT for the Evaluation of Atherosclerosis and Inflammation. Clin Med Insights Cardiol. 2015; 8(Suppl 3): 13-21. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.